Malignant neoplasm of prostate
|
0.140 |
GeneticVariation
|
disease |
GWASDB |
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
|
23535732 |
2013 |
Fasting blood glucose measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways.
|
22885924 |
2012 |
Fasting blood sugar result
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways.
|
22885924 |
2012 |
Marijuana Abuse
|
0.310 |
Biomarker
|
disease |
PSYGENET |
The G allele of SNP rs596359, in the RGS17 promoter region, was associated with AD, CD, OD, or MjD in both populations (0.005≤P(empirical)≤0.019).
|
22591552 |
2012 |
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Through microarray and gene expression analysis, we show that expression of RGS17 is up-regulated in 80% of lung tumors, and also up-regulated in prostate tumors.
|
19244110 |
2009 |
Prostate carcinoma
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
|
23535732 |
2013 |
Prostate carcinoma
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Exome-wide association study of plasma lipids in >300,000 individuals.
|
29083408 |
2017 |
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.
|
30224653 |
2018 |
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study identifies 112 new loci for body mass index in the Japanese population.
|
28892062 |
2017 |
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study.
|
26426971 |
2015 |
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A Large Multiethnic Genome-Wide Association Study of Adult Body Mass Index Identifies Novel Loci.
|
30108127 |
2018 |
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
Amphetamine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
Amphetamine Addiction
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
Amphetamine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association for methamphetamine dependence: convergent results from 2 samples.
|
18316681 |
2008 |
Marijuana Abuse
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
The G allele of SNP rs596359, in the RGS17 promoter region, was associated with AD, CD, OD, or MjD in both populations (0.005≤P(empirical)≤0.019).
|
22591552 |
2012 |
Malignant neoplasm of prostate
|
0.140 |
Biomarker
|
disease |
BEFREE |
Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.
|
29351497 |
2018 |
Malignant neoplasm of prostate
|
0.140 |
Biomarker
|
disease |
BEFREE |
Our findings revealed that miR-203/RGS17 axis might be a potential therapeutic target for the treatment of PCa.
|
31298318 |
2019 |
Malignant neoplasm of prostate
|
0.140 |
Biomarker
|
disease |
BEFREE |
Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products.
|
28621943 |
2017 |
Malignant neoplasm of prostate
|
0.140 |
Biomarker
|
disease |
BEFREE |
RGS17: an emerging therapeutic target for lung and prostate cancers.
|
23734683 |
2013 |